This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.
Laleh Amiri-Kordestani, MD
Advertisement
Articles by Laleh Amiri-Kordestani, MD
Advertisement
Latest Updated Articles
- Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives
Published: November 16th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
2
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
3
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
4
Silevertinib Displays Robust Antitumor Activity in EGFR-Mutated NSCLC
5
